US Patent

US11179402 — Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same

Composition of Matter · Assigned to Clarus Therapeutics Inc · Expires 2026-04-14 · 0y expired

Vulnerability score 7/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a drug delivery system for oral administration of hydrophobic drugs, including formulations of testosterone and its esters, such as testosterone palmitate.

USPTO Abstract

A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US11179402
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-04-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Clarus Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.